Jetbio

Jetbio is at the forefront of commercializing advanced 3D bioprinting technology developed at Newcastle University. The company specializes in reactive jet impingement (ReJI) bioprinting systems, which are designed to print biomimetic cell-filled gels. These systems are pivotal in creating in vitro disease models for drug testing and supporting tissue engineering and regenerative medicine applications. Jetbio's technology addresses the lengthy and costly drug development process by providing a fast, flexible, and accurate solution that reduces reliance on animal testing. The company collaborates with leading academic institutions, including the Universities of Cambridge, Newcastle, and Bristol, to further develop and apply its technology. Jetbio's business model focuses on selling and supporting its bioprinting systems to research institutions and pharmaceutical companies, generating revenue through equipment sales and potential service agreements. The market for Jetbio's products includes the biomedical research sector, particularly those involved in drug development and regenerative medicine. Keywords: 3D bioprinting, biomimetic gels, drug testing, regenerative medicine, reactive jet impingement, Newcastle University, tissue engineering, in vitro models, biomedical research, collaboration.